16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer
Publication
, Conference
Alvarez Secord, A; Bookman, M; Coleman, R; Dinh, M; Khandelwal, N; Benjamin, K; Kamalakar, R; Sullivan, D; Cella, D
Published in: Oral Plenary
November 2020
Duke Scholars
Published In
Oral Plenary
DOI
Publication Date
November 2020
Publisher
BMJ Publishing Group Ltd
Conference Name
IGCS 2020 Annual Meeting Abstracts
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Alvarez Secord, A., Bookman, M., Coleman, R., Dinh, M., Khandelwal, N., Benjamin, K., … Cella, D. (2020). 16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer. In Oral Plenary. BMJ Publishing Group Ltd. https://doi.org/10.1136/ijgc-2020-igcs.16
Alvarez Secord, A., M. Bookman, R. Coleman, M. Dinh, N. Khandelwal, K. Benjamin, R. Kamalakar, D. Sullivan, and D. Cella. “16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer.” In Oral Plenary. BMJ Publishing Group Ltd, 2020. https://doi.org/10.1136/ijgc-2020-igcs.16.
Alvarez Secord A, Bookman M, Coleman R, Dinh M, Khandelwal N, Benjamin K, et al. 16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer. In: Oral Plenary. BMJ Publishing Group Ltd; 2020.
Alvarez Secord, A., et al. “16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer.” Oral Plenary, BMJ Publishing Group Ltd, 2020. Crossref, doi:10.1136/ijgc-2020-igcs.16.
Alvarez Secord A, Bookman M, Coleman R, Dinh M, Khandelwal N, Benjamin K, Kamalakar R, Sullivan D, Cella D. 16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer. Oral Plenary. BMJ Publishing Group Ltd; 2020.
Published In
Oral Plenary
DOI
Publication Date
November 2020
Publisher
BMJ Publishing Group Ltd
Conference Name
IGCS 2020 Annual Meeting Abstracts
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis